keyword
MENU ▼
Read by QxMD icon Read
search

Reviews in oncology

keyword
https://www.readbyqxmd.com/read/29676695/huge-heterogeneity-in-survival-in-a-subset-of-adult-patients-with-resected-wild-type-isocitrate-dehydrogenase-status-who-grade-ii-astrocytomas
#1
Gaëtan Poulen, Catherine Gozé, Valérie Rigau, Hugues Duffau
OBJECTIVE World Health Organization grade II gliomas are infiltrating tumors that inexorably progress to a higher grade of malignancy. However, the time to malignant transformation is quite unpredictable at the individual patient level. A wild-type isocitrate dehydrogenase (IDH-wt) molecular profile has been reported as a poor prognostic factor, with more rapid progression and a shorter survival compared with IDH-mutant tumors. Here, the oncological outcomes of a series of adult patients with IDH-wt, diffuse, WHO grade II astrocytomas (AII) who underwent resection without early adjuvant therapy were investigated...
April 20, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29675778/systematic-review-of-the-mesopancreas-concept-and-clinical-implications
#2
REVIEW
J M Ramia, R De-la-Plaza, A Manuel-Vazquez, A Lopez-Marcano, R Morales
BACKGROUND: In 2007, Gockel et al. coined the term mesopancreas (MP). In the next 10 years, a limited number of publications about MP have been published, but little is known about the oncological benefit of MP resection. We performed a systematic review of the literature on MP. METHODS: An electronic search was performed in PubMed, EMBASE, Cochrane, Latindex, Scielo, and Koreamed databases until 15 June 2017 to identify all published articles dealing with the subject of MP...
April 19, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29674411/sequential-apparent-diffusion-coefficient-for-assessment-of-tumor-progression-in-patients-with-low-grade-glioma
#3
I E Chen, N Swinburne, N M Tsankova, M M Hefti, A Aggarwal, A H Doshi, A Hormigo, B N Delman, K Nael
BACKGROUND AND PURPOSE: Early and accurate identification of tumor progression in patients with low-grade gliomas is challenging. We aimed to assess the role of quantitative ADC analysis in the sequential follow-up of patients with low-grade gliomas as a potential imaging marker of tumor stability or progression. MATERIALS AND METHODS: In this retrospective study, patients with a diagnosis of low-grade glioma with at least 12 months of imaging follow-up were retrospectively reviewed...
April 19, 2018: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29674013/the-tipping-point-key-oncologic-imaging-findings-resulting-in-critical-changes-in-the-management-of-malignant-tumors-of-the-gastrointestinal-tract
#4
REVIEW
Jonathan Wu, Lipika Goyal, Ryan Nipp, Jennifer Wo, Motaz Qadan, Raul N Uppot
OBJECTIVE: The purpose of this article is to review tumor staging systems for gastrointestinal tumors including pancreatic adenocarcinoma, hepatocellular carcinoma, cholangiocarcinoma, gastric adenocarcinoma, small bowel adenocarcinoma, rectal carcinoma, and anal carcinoma and identify the key imaging findings ("tipping points"), which change patient management based on changes in tumor staging. CONCLUSION: For all malignant gastrointestinal tumors, there are key imaging findings ("tipping points") including tumor size, tumor extension, lymphadenopathy, vascular invasion, and distant metastasis that dictate patient management and prognosis, based on changes in tumor stage...
January 31, 2018: Current Problems in Diagnostic Radiology
https://www.readbyqxmd.com/read/29673906/interest-of-next-generation-sequencing-in-bcg-treated-high-risk-bladder-cancer
#5
C Jungels, N Martinez Chanza, S Albisinni, M Mercier, N d'Haene, S Rorive, T Roumeguère
OBJECTIVES: There are only few predictive factors for response of non-musculo-invasive bladder cancer (NMIBC) to Bacillus Calmette-Guérin (BCG) therapy. Our study analyzed the results of the sequencing of new generation (NGS) targeted on 50 genes of oncological interest obtained on bladder resection parts in high-risk NMIBC patients treated with BCG, to describe this population from a molecular point of view and try to correlate these results in patients who present or not recurrence after BCG...
April 16, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29673807/frequency-and-impact-of-grade-three-or-four-toxicities-of-novel-agents-on-outcomes-of-older-patients-with-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma-alliance-a151611
#6
Michael Tallarico, Jared C Foster, Drew Seisler, Jacqueline M Lafky, Arti Hurria, Aminah Jatoi, Harvey J Cohen, Hyman B Muss, Nancy Bartlett, Bruce D Cheson, Sin-Ho Jung, John P Leonard, John C Byrd, Chadi Nabhan
OBJECTIVE: Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. PATIENTS AND METHODS: We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014...
April 16, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29673712/update-on-systemic-prostate-cancer-therapies-management-of-metastatic-castration-resistant-prostate-cancer-in-the-era-of-precision-oncology
#7
REVIEW
Philipp Nuhn, Johann S De Bono, Karim Fizazi, Stephen J Freedland, Maurizio Grilli, Philip W Kantoff, Guru Sonpavde, Cora N Sternberg, Srinivasan Yegnasubramanian, Emmanuel S Antonarakis
CONTEXT: Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the same time, understanding of optimal patient selection, effective sequential use, and development of resistance patterns remains incomplete. OBJECTIVE: To review current systemic therapies and recent advances in drug development for mCRPC and strategies to aid in patient selection and optimal sequencing...
April 16, 2018: European Urology
https://www.readbyqxmd.com/read/29670897/searching-for-clinically-relevant-biomarkers-in-geriatric-oncology
#8
REVIEW
Theodora Katsila, George P Patrinos, Dimitrios Kardamakis
Ageing, which is associated with a progressive decline and functional deterioration in multiple organ systems, is highly heterogeneous, both inter- and intraindividually. For this, tailored-made theranostics and optimum patient stratification become fundamental, when decision-making in elderly patients is considered. In particular, when cancer incidence and cancer-related mortality and morbidity are taken into account, elderly patient care is a public health concern. In this review, we focus on oncogeriatrics and highlight current opportunities and challenges with an emphasis on the unmet need of clinically relevant biomarkers in elderly cancer patients...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29670046/resistance-to-anti-angiogenic-therapy-in-cancer-alterations-to-anti-vegf-pathway
#9
REVIEW
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, Yoshiharu Sakai
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy...
April 18, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29669264/photodynamic-therapy-with-topical-photosensitizers-in-mucosal-and-semimucosal-areas-review-from-a-dermatologic-perspective
#10
REVIEW
Vieri Grandi, Maurizio Sessa, Luigi Pisano, Riccardo Rossi, Arturo Galvan, Riccardo Gattai, Moira Mori, Luana Tiradritti, Stefano Bacci, Giuliano Zuccati, Pietro Cappugi, Nicola Pimpinelli
Photodynamic Therapy is a procedure based on the interaction between a Photo Sensitizer, a light source with a specific wavelength and oxygen. Aim of this Review is to provide a brief and updated analysis of scientific reports of the use of PDT with topical PS in the management of oncological, infectious, and inflammatory disorders involving mucosal and semimucosal areas, with a specific focus on diseases of dermatologic interest.
April 15, 2018: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29669165/the-state-of-survivorship-care-in-radiation-oncology-results-from-a-nationally-distributed-survey
#11
Melissa A Frick, Seth A Rosenthal, Neha Vapiwala, Brian T Monzon, Abigail T Berman
BACKGROUND: Survivorship care has become an increasingly critical component of oncologic care as well as a quality practice and reimbursement metric. To the authors' knowledge, the current climate of survivorship medicine in radiation oncology has not been investigated fully. METHODS: An institutional review board-approved, Internet-based survey examining practices and preparedness in survivorship care was distributed to radiation oncology practices participating in the American College of Radiology Radiation Oncology Practice Accreditation program between November 2016 and January 2017...
April 18, 2018: Cancer
https://www.readbyqxmd.com/read/29668669/pancreatic-neuroendocrine-neoplasms-a-role-of-laparoscopy-in-surgical-treatment-review
#12
Jacek Szeliga, Marek Jackowski
Pancreatic neuroendocrine neoplasms (PNENs) are extremely rare neoplasms of the pancreas. They originate from pancreatic islet cells, and from the very beginning, cancer cells may or may not show hormone hypersecretion. Currently, surgical treatment is the only therapeutic method that significantly prolongs life expectancy, and in such cases it is a method of choice. In the paper, a review of literature based on the Medline database and including mainly the period of 2013 to 2017 was performed. In each case an operating surgeon is responsible for selection of a method used for surgical treatment...
April 17, 2018: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
https://www.readbyqxmd.com/read/29668542/clinical-trial-enrollment-is-associated-with-improved-follow-up-rates-among-survivors-of-childhood-cancer
#13
Kelley K Hutchins, Süreyya Savaşan, Ronald L Thomas, Laura A Strathdee, Zhihong J Wang, Jeffrey W Taub
Fortunately >80% of children diagnosed with cancer become long-term survivors; however, this population is at a significantly increased risk of morbidity and mortality as a result of their previous cancer therapy, and long-term follow-up (LTFU) is critical. Multiple barriers to receiving adequate LTFU care have been studied. We investigated whether lack of enrollment in a therapeutic clinical trial may be a barrier to receiving LTFU care. We conducted a review of 353 patient records at the Children's Hospital of Michigan enrolled in our Children's Oncology Group registry between January 1, 2005 and December 31, 2010...
April 17, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29668402/retroperitoneal-laparoscopic-partial-nephrectomy-versus-radical-nephrectomy-for-clinical-t1-renal-hilar-tumor-comparison-of-perioperative-characteristics-and-short-term-functional-and-oncologic-outcomes
#14
Chuance Yang, Zhenlong Wang, Shanlong Huang, Li Xue, Delai Fu, Tie Chong
PURPOSE: To present our single-center experience with retroperitoneal laparoscopic partial nephrectomy (LPN) and retroperitoneal laparoscopic radical nephrectomy (LRN) for T1 renal hilar tumors and evaluate which one is better. METHODS: A retrospective review of 63 patients with hilar tumors undergoing retroperitoneal LPN or LRN was performed. The perioperative characteristics, change in estimated glomerular filtration rate (eGFR) from baseline to month 3, and oncologic outcomes were summarized...
April 18, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/29668367/which-patients-with-cervical-squamous-cell-carcinoma-might-benefit-from-neoadjuvant-chemotherapy
#15
Omar Mahmoud, Mark H Einstein
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
April 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29667725/parent-centered-communication-at-time-of-pediatric-cancer-diagnosis-a-systematic-review
#16
REVIEW
Cristiana Hentea, Erika R Cheng, Nerissa S Bauer, Emily L Mueller
There are limited data focused on parental communication needs surrounding the time when a child is diagnosed with cancer. In this systematic review, we synthesized current literature on communication preferences of parents at the time of their child's diagnosis of cancer. We identified 16 studies that yielded 4 major themes parents recognized as important: communication style, content, logistics, and healthcare team. We further identified several concepts that inform parent-centered communication practice...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667385/chance-of-reimbursement-for-add-on-therapies-in-poland-and-in-the-world-review-of-the-reimbursement-recommendations
#17
Ewa Borowiack, Magdalena Marzec, Anna Nowotarska, Joanna Jarosz, Agata Orkisz, Patrycja Prząda-Machno
INTRODUCTION: Oncology drugs combined with standard therapies (so-called add-on therapies, e.g. bevacizumab, palbociclib) often receive negative recommendations regarding the legitimacy of public financing, issued by government agencies responsible for their assessment, i.e. health technology assessment agencies. The aim of the study was to estimate the scale of the problem related to the reimbursement of add-on therapies used in the treatment of breast and genitourinary cancers in Poland and in the world...
2018: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/29667346/in-situ-vaccination-harvesting-low-hanging-fruit-on-the-cancer-immunotherapy-tree
#18
REVIEW
Mee Rie Sheen, Steven Fiering
After 100 years of debate, it is clear that cancer is recognized by the immune system and this has generated immense interest in cancer immunotherapy. The systemic nature of the immune system gives immunotherapy the ability to treat metastatic disease, which currently requires chemotherapy that frequently fails. Like chemotherapy, most immunotherapy is systemically applied in an effort to generate systemic antitumor immune response. However, local administration of immunostimulatory reagents into a recognized tumor by in situ vaccination (ISV) can also generate systemic antitumor immunity to fight metastatic disease...
April 18, 2018: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/29667344/concise-review-aggressive-colorectal-cancer-role-of-epithelial-cell-adhesion-molecule-in-cancer-stem-cells-and-epithelial-to-mesenchymal-transition
#19
REVIEW
Maximilian Boesch, Gilbert Spizzo, Andreas Seeber
Colorectal cancer (CRC) is one of the most common malignancies worldwide. In spite of various attempts to ameliorate outcome by escalating treatment, significant improvement is lacking particularly in the adjuvant setting. It has been proposed that cancer stem cells (CSCs) and the epithelial-to-mesenchymal transition (EMT) are at least partially responsible for therapy resistance in CRC. The epithelial cell adhesion molecule (EpCAM) was one of the first CSC antigens to be described. Furthermore, an EpCAM-specific antibody (edrecolomab) has the merit of having launched the era of monoclonal antibody treatment in oncology in the 1990s...
April 17, 2018: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/29666835/aptamers-and-apple-pies-a-mini-review-of-psma-aptamers-and-lessons-from-donald-s-coffey
#20
REVIEW
Shawn E Lupold
This mini-review article is part of a special issue dedicated to Donald S. Coffey, a pioneer translational research scientist, exemplary mentor, and leader in urologic and urologic oncology research. This article first briefly reflects on life and scientific lessons from Don Coffey. It then reviews the development of two prostate cancer targeting RNA aptamers, xPSM-A9 and xPSM-A10, through in vitro selection for aptamers that bind to the extracellular domain of the Prostate Specific Membrane Antigen (PSMA)...
2018: American Journal of Clinical and Experimental Urology
keyword
keyword
77587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"